Back to top
more

Horizon Therapeutics Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$102.61 USD

102.61
1,398,505

+0.11 (0.11%)

Updated Jul 29, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Horizon Therapeutics (HZNP) Reports Next Week: Wall Street Expects Earnings Growth

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPKO Health (OPK) Inks Licensing Deal for AntagoNAT Technology

OPKO Health's (OPK) latest licensing agreement is expected to advance the development and commercialization of potential disease-modifying therapeutics, especially for Dravet syndrome.

Horizon (HZNP) Begins Phase II Study for Lupus Candidate

Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.

OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility

OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.

Horizon Therapeutics (HZNP) Down 1.8% Since Last Earnings Report: Can It Rebound?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

Horizon Therapeutics (HZNP) Misses Q1 Earnings Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -57.14% and 4.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

John Blank headshot

Will Central Banks Start to Care About Fundamentals?

Macro-data has been much stronger than expected.¿¿¿¿¿¿ Still, the only thing that matters is NOT whether stock traders (or pundits) take note of strong data. It is whether the Fed and other major central banks care.

Can Horizon Therapeutics (HZNP) Keep the Earnings Surprise Streak Alive?

Horizon Therapeutics (HZNP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BMY or HZNP: Which Is the Better Value Stock Right Now?

BMY vs. HZNP: Which Stock Is the Better Value Option?

Why Is Horizon Therapeutics (HZNP) Down 8.1% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immunovant (IMVT) Gains on a Potential Buyout by Roivant

Immunovant (IMVT) gains following Roivant's announcement of a possible buyout of the company. Roivant is a major stakeholder of Immunovant.

Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat

Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.

Company News for Feb 25, 2021

Companies In The News Are: VCEL, LNG, HZNP, PRAH

Halozyme (HALO) Q4 Earnings Miss, 2021 View Weak, Stock Falls

Halozyme (HALO) reports lower-than-expected fourth-quarter earnings. However, revenues beat estimates. The company's outlook for 2021 is below market expectations.

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Surpass Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 21.90% and 7.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon Therapeutics (HZNP) to Acquire Viela Bio for $3.05B

Horizon Therapeutics (HZNP) is set to buy Viela Bio for $3.05 billion to expand its pipeline and accelerate growth.

Horizon (HZNP) Provides Preliminary 2020 Financial Results

Horizon (HZNP) provides 2020 preliminary financial results and updates on its key drugs.

New Strong Sell Stocks for January 6th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Horizon Therapeutics (HZNP) Down 6.7% Since Last Earnings Report: Can It Rebound?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts

Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza in 2021. It is making efforts to expand the label for its marketed drugs.

Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology

Horizon (HZNP) inks deal to get an exclusive access to Halozyme's ENHANZE drug delivery technology for subcutaneous formulation of medicines targeting IGF-1R.

Is Horizon Therapeutics (HZNP) a Worthy Stock Now?

Let's see if Horizon Therapeutics (HZNP) stock is a good choice for value-oriented investors right now from multiple angles.